ArticleJournal of translational medicine2021
Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts.
Article in Journal of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- Mesenchymal stem cell-derived microvesicles confer protection against rheumatoid arthritis-associated interstitial lung disease.Stem cell research & therapy · 2026Article
- Safety and clinical considerations of alopecia therapies during pregnancy, fertility treatment, and polycystic ovary syndrome workup.International journal of women's dermatology · 2026Review
- Phosphatidylserine liposomes containing metformin mitigate experimental atopic dermatitis: evidence for Akt/mTOR pathway involvement.Inflammopharmacology · 2026Article
- Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches.Frontiers in immunology · 2026Review
- Modulation of Master Transcription Factor Expression of Nile Tilapia Leukocytes via Cholinergic Pathways.International journal of molecular sciences · 2025Article
- Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review.American journal of clinical dermatology · 2025Review
- The Pathogenic Role of T Cell Metabolism and its Effect on Immune Senescence in Autoimmune Diseases and Infection.Clinical reviews in allergy & immunology · 2025Review
- Metformin as a Metabolic Adjuvant to Amoxicillin: A Hypothesis on Synergistic Antibacterial Action.Advanced pharmaceutical bulletin · 2025Article
- Vitamin D and skin disorders: bridging molecular insights to clinical innovations.Molecular medicine (Cambridge, Mass.) · 2025Review
- A Self-Adhesive Ginsenoside Rk3/Metformin-Loaded Hydrogel Microneedle for Management of Systemic Sclerosis.Gels (Basel, Switzerland) · 2025Article
- Vimentin immunization induces TH2/TH17 cell activation and autoantibody production in a novel mouse model of bleomycin induced systemic sclerosis.Frontiers in immunology · 2025Article
- Adipose-Derived Stem-Cell-Membrane-Coated PLGA-PEI Nanoparticles Promote Wound Healing via Efficient Delivery of miR-21.Pharmaceutics · 2024Article
- Review
- The Novel Cytokine Interleukin-41/Meteorin-like Is Reduced in Diffuse Systemic Sclerosis.Cells · 2024Article
- The amelioration effect of antidiabetic agents on cytokine expression in patients with type 2 diabetes mellitus.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- MicroRNA-21a-5p inhibition alleviates systemic sclerosis by targeting STAT3 signaling.Journal of translational medicine · 2024Article
- Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa.The British journal of dermatology · 2023Article
- Influence of Age, Gender, Frailty, and Body Mass Index on Serum IL-17A Levels in Mature Type 2 Diabetic Patients.Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- Anti‑inflammatory effect of metformin against an experimental model of LPS‑induced cytokine storm.Experimental and therapeutic medicine · 2023Article
- Impaired Regulation by IL-35 in Systemic Sclerosis.International journal of molecular sciences · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleroderma is an autoimmune disease that causes dermal fibrosis. It occurs when collagen accumulates in tissue as a result of persistent inflammation. Th17 cells and pro-inflammatory cytokines such as IL-1β, IL-6, IL-17, and TNF-α play important roles in the pathogenesis of scleroderma. Because metformin, a medication used to treat diabetes, has effective immunoregulatory functions, we investigated its therapeutic function in scleroderma. Mice in a model of bleomycin-induced scleroderma were treated with metformin for 2 weeks. Histological assessment demonstrated protective effects of metformin against scleroderma. Metformin decreased the expression of pro-inflammatory factors in dermal tissue and lymphocytes. It also decreased mRNA expression of pro-inflammatory cytokines (IL-1β, IL-6, IL-17, and TNF-α) and fibrosis-inducing molecules both in vivo and in vitro. These results suggest that metformin treatment has anti-inflammatory effects on lymphocytes via the inhibition of IL-17 and cytokines related to Th17 differentiation, such as IL-1β, IL-6, and TNF-α. To investigate how metformin modulates the inflammatory process in skin fibroblasts, we measured mTOR-STAT3 signaling in skin fibroblasts and found that phosphorylated mTOR and phosphorylated STAT3 protein expression were decreased by metformin treatment. These results suggest that metformin has potential to treat scleroderma by inhibiting pro-inflammatory cytokines and anti-inflammatory activity mediated by mTOR-STAT3 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.